2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1331

Factors Associated with Pain in Children with Hypermobility – a Pilot Study
Abstract Number: 1066

Factors Associated with Recording of Rheumatoid Arthritis on Death Certificate
Abstract Number: 2025

Factors Associated with Time to Diagnosis from Symptom Onset in Early Rheumatoid Arthritis Patients
Abstract Number: 2440

Factors Influencing Health Related Quality of Life (HR-QOL) for Korean Patients with Rheumatoid Arthritis
Abstract Number: 231

Factors Predicting Fracture in the over-75s: An Observational Case-Control Study
Abstract Number: 1776

Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
Abstract Number: 788

Fast-Track Diagnostic Procedure for Giant Cell Arteritis
Abstract Number: 2986

Fat Metaplasia on MRI of the Sacroiliac Joints Is a Lead Indicator of Radiographic Progression in the Spine of Patients with Ankylosing Spondylitis
Abstract Number: 2372

Fatigue and Related Factors in Patients with Rheumatoid Arthritis Treated with Tocilizumab in Daily Clinical Setting
Abstract Number: 377

Fatigue Fluctuates Substantially over Time in Rheumatoid Arthritis Patients Despite Stable Disease Activity during Treatment with Biological Agents
Abstract Number: 2607

Fatigue in Ankylosing Spondylitis: A Multivariable Analysis Implicates Inflammation As the Key Determinant of Disability
Abstract Number: 2704

Fatigue in Systemic Sclerosis
Abstract Number: 2049

Fatigue Is a Risk Factor for Subsequent Functional Decline in SLE
Abstract Number: 672

Favorable Response to Belimumab in Pediatric-Onset Systemic Lupus Erythematosus
Abstract Number: 989

Fcgamma Receptor IIb Facilitates Rapid Internalisation of Rituximab (type 1 anti-CD20 antibody) in B Cells from Patients with RA and SLE and Contributes to Less Efficient B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].